WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.


L04 IMMUNOSUPPRESSANTS

Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.


L04A IMMUNOSUPPRESSANTS

This group comprises immunosuppressants excl. corticosteroids.

The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.


L04AX Other immunosuppressants

Oral formulations and prefilled syringe/pen of methotrexate are classified in this group. Parenteral formulations used for neoplastic diseases are classified in L01BA01.
Dimethyl fumarate indicated for multiple sclerosis or plaque psoriasis is classified here.

The DDD for thalidomide is based on the treatment of lepra.
The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.
The DDD for pomalidomide is based on the starting dose in the treatment of multiple myeloma.
The DDDs for methotrexate are based on the treatment of rheumatoid arthritis.


    ATC code  Name  DDD  U Adm.R Note
    L04AX02 thalidomide 0.1 

List of abbreviations

Last updated: 2024-01-26